The North America Plasma Protein Therapeutics Market would witness market growth of 4.5% CAGR during the forecast period (2023-2029).
Protein components fractionated from human plasma are used to prevent, manage, and treat life-threatening illnesses brought on by trauma, immunologic disorders, congenital deficits, or infections. Frequently, these treatments are the only ones available. However, much has changed in the last few years to enhance immunoglobulin G recovery, improve product purity, and isolate new plasma proteins like von Willebrand factor, α1-protease inhibitor, and protein C.
Fractionation refers to the industrial procedure utilized to separate therapeutic plasma proteins. In batches of several thousand liters, in around 70 plants, more than 23 to 28 million liters of human plasma are fractionated annually. Modern plasma fractionation integrates industrial processes to isolate, sequentially and cohesively, the crude portions further refined into specific medicinal products. A beginning plasma pool that may have had infectious pathogens in it is rendered inactive or removed by verified specific processes. This complicated industrial process is carried out in plasma fractionation factories that are licensed facilities that are operated in accordance with good manufacturing practices as well as according to quality assurance criteria.
According to the CDC's October 2021 update, an estimated 78.4 million persons age 18 and older would likely have arthritis that has been officially diagnosed by 2040. The goal of platelet-rich plasma therapy, also known as PRP therapy or autologous conditioned plasma (ACP) therapy, is to use the blood's inherent ability to mend to restore injured tendons, ligaments, muscles, cartilage, or even bone. Arthritis is now being treated using therapy. Therefore, it is projected that the rising number of arthritis patients in the United States would open up prospects for cutting-edge plasma protein therapies. In light of this, the regional market is anticipated to experience significant growth over the forecast period due to the rise in blood-related disorders, rising incidence and prevalence of autoimmune and neurological ailments, and research and development in plasma protein.
The US market dominated the North America Plasma Protein Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $11,658.6 Million by 2029. The Canada market is poised to grow at a CAGR of 6.8% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 5.9% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals, and Others. Based on Product Type, the market is segmented into Immunoglobulin, Albumin, Plasma derived factor VIII, and Others. Based on Application, the market is segmented into Hemophilia, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Plasma Protein Therapeutics Market is Projected to reach USD 39.1 Billion by 2029, at a CAGR of 5.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Abeona Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Grifols, S.A., Baxter International, Inc., Kedrion S.p.A, Octapharma AG, CSL Limited (CSL Behring), Taibang Biological Group Co., Ltd and ADMA Biologics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
By Product Type
- Immunoglobulin
- Albumin
- Plasma derived factor VIII
- Others
By Application
- Hemophilia
- Idiopathic Thrombocytopenic Purpura
- Primary Immunodeficiency Disorder
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG
- Abeona Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Baxter International, Inc.
- Kedrion S.p.A
- Octapharma AG
- CSL Limited (CSL Behring)
- Taibang Biological Group Co., Ltd
- ADMA Biologics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Plasma Protein Therapeutics Market, by End User
1.4.2 North America Plasma Protein Therapeutics Market, by Product Type
1.4.3 North America Plasma Protein Therapeutics Market, by Application
1.4.4 North America Plasma Protein Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2020, Jun – 2023, Mar) Leading Players
Chapter 4. North America Plasma Protein Therapeutics Market by End User
4.1 North America Hospitals Market by Country
4.2 North America Others Market by Country
Chapter 5. North America Plasma Protein Therapeutics Market by Product Type
5.1 North America Immunoglobulin Market by Country
5.2 North America Albumin Market by Country
5.3 North America Plasma derived factor VIII Market by Country
5.4 North America Others Market by Country
Chapter 6. North America Plasma Protein Therapeutics Market by Application
6.1 North America Hemophilia Market by Country
6.2 North America Idiopathic Thrombocytopenic Purpura Market by Country
6.3 North America Primary Immunodeficiency Disorder Market by Country
6.4 North America Others Market by Country
Chapter 7. North America Plasma Protein Therapeutics Market by Country
7.1 US Plasma Protein Therapeutics Market
7.1.1 US Plasma Protein Therapeutics Market by End User
7.1.2 US Plasma Protein Therapeutics Market by Product Type
7.1.3 US Plasma Protein Therapeutics Market by Application
7.2 Canada Plasma Protein Therapeutics Market
7.2.1 Canada Plasma Protein Therapeutics Market by End User
7.2.2 Canada Plasma Protein Therapeutics Market by Product Type
7.2.3 Canada Plasma Protein Therapeutics Market by Application
7.3 Mexico Plasma Protein Therapeutics Market
7.3.1 Mexico Plasma Protein Therapeutics Market by End User
7.3.2 Mexico Plasma Protein Therapeutics Market by Product Type
7.3.3 Mexico Plasma Protein Therapeutics Market by Application
7.4 Rest of North America Plasma Protein Therapeutics Market
7.4.1 Rest of North America Plasma Protein Therapeutics Market by End User
7.4.2 Rest of North America Plasma Protein Therapeutics Market by Product Type
7.4.3 Rest of North America Plasma Protein Therapeutics Market by Application
Chapter 8. Company Profiles
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Grifols, S.A
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.2.5.3 Acquisition and Mergers:
8.2.5.4 Geographical Expansions:
8.3 Takeda Pharmaceutical Company Limited
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.3.5.3 Geographical Expansions:
8.4 Kedrion S.p.A
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Acquisition and Mergers:
8.5 ADMA Biologics, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Approvals and Trials:
8.6 Octapharma AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Approvals and Trials:
8.7 CSL Limited (CSL Behring)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expense
8.9 Abeona Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.10. Taibang Biologic Group
8.10.1 Company Overview
TABLE 1 North America Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 North America Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Plasma Protein Therapeutics Market
TABLE 4 Product Launches And Product Expansions– Plasma Protein Therapeutics Market
TABLE 5 Acquisition and Mergers– Plasma Protein Therapeutics Market
TABLE 6 Geographical expansions – Plasma Protein Therapeutics Market
TABLE 7 approvals and trials – Plasma Protein Therapeutics Market
TABLE 8 North America Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 9 North America Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 10 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 11 North America Hospitals Market by Country, 2023 - 2029, USD Million
TABLE 12 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 13 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 14 North America Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 15 North America Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 16 North America Immunoglobulin Market by Country, 2019 - 2022, USD Million
TABLE 17 North America Immunoglobulin Market by Country, 2023 - 2029, USD Million
TABLE 18 North America Albumin Market by Country, 2019 - 2022, USD Million
TABLE 19 North America Albumin Market by Country, 2023 - 2029, USD Million
TABLE 20 North America Plasma derived factor VIII Market by Country, 2019 - 2022, USD Million
TABLE 21 North America Plasma derived factor VIII Market by Country, 2023 - 2029, USD Million
TABLE 22 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 23 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 24 North America Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 25 North America Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 26 North America Hemophilia Market by Country, 2019 - 2022, USD Million
TABLE 27 North America Hemophilia Market by Country, 2023 - 2029, USD Million
TABLE 28 North America Idiopathic Thrombocytopenic Purpura Market by Country, 2019 - 2022, USD Million
TABLE 29 North America Idiopathic Thrombocytopenic Purpura Market by Country, 2023 - 2029, USD Million
TABLE 30 North America Primary Immunodeficiency Disorder Market by Country, 2019 - 2022, USD Million
TABLE 31 North America Primary Immunodeficiency Disorder Market by Country, 2023 - 2029, USD Million
TABLE 32 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 33 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 34 North America Plasma Protein Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 35 North America Plasma Protein Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 36 US Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 37 US Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 38 US Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 39 US Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 40 US Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 41 US Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 42 US Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 43 US Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 44 Canada Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 45 Canada Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 46 Canada Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 47 Canada Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 48 Canada Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 49 Canada Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 50 Canada Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 51 Canada Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 52 Mexico Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 53 Mexico Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 54 Mexico Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 55 Mexico Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 56 Mexico Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 57 Mexico Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 58 Mexico Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 59 Mexico Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 60 Rest of North America Plasma Protein Therapeutics Market, 2019 - 2022, USD Million
TABLE 61 Rest of North America Plasma Protein Therapeutics Market, 2023 - 2029, USD Million
TABLE 62 Rest of North America Plasma Protein Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 63 Rest of North America Plasma Protein Therapeutics Market by End User, 2023 - 2029, USD Million
TABLE 64 Rest of North America Plasma Protein Therapeutics Market by Product Type, 2019 - 2022, USD Million
TABLE 65 Rest of North America Plasma Protein Therapeutics Market by Product Type, 2023 - 2029, USD Million
TABLE 66 Rest of North America Plasma Protein Therapeutics Market by Application, 2019 - 2022, USD Million
TABLE 67 Rest of North America Plasma Protein Therapeutics Market by Application, 2023 - 2029, USD Million
TABLE 68 Key Information – Bayer AG
TABLE 69 Key information – Grifols, S.A.
TABLE 70 Key Information – Takeda Pharmaceutical Company Limited
TABLE 71 key Information – Kedrion S.p.A
TABLE 72 Key Information – ADMA Biologics, Inc.
TABLE 73 Key Information – Octapharma AG
TABLE 74 key Information – CSL Limited
TABLE 75 Key Information – Baxter International, Inc.
TABLE 76 Key Information – Abeona Therapeutics, Inc.
TABLE 77 Key Information – Taibang Biologic Group
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Acquisitions and Mergers : 2020, Jun – 2023, Mar) Leading Players
FIG 5 Swot analysis: bayer ag
FIG 6 Recent strategies and developments: Grifols, S.A.
FIG 7 Recent strategies and developments: Takeda Pharmaceutical Company Limited
FIG 8 Recent strategies and developments: Kedrion S.p.A